A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma


NCT Number:



Study Status:






This study is being done to answer the following question: Can we shrink or stabilize your brain cancer by adding immune therapy drugs to the usual radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your recurrent glioblastoma. The usual approach is defined as care most people get for recurrent glioblastoma.

Are you Eligible? (Inclusion Criteria)

  • Are you 18 years of age or older?
  • Have you been diagnosed with glioblastoma that has come back after previous
  • radiation therapy?
  • Are you able to make regularly scheduled visits to the clinic for treatment and
  • examinations?

Specialty Area(s)

Principal Investigator

Profile Headshot
  • Deputy Director, Division of Neuro-Oncology

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032